The Only Vaccine Stocks to Consider Now

Months into the pandemic, there are still no signs of improvement.

As of now, there are nearly 40 million global cases, with 1.1 million deaths. In the U.S., the count is up to 8.14 million. India is up to nearly 75 Million. Brazil is up to 5.2 million. Russia is nearing 1.4 million. Colombia is up to 952,373.

In Paris, and in eight other cities, restaurants, bars, theaters, and other businesses must now close no later than 9pm. In London, people from different households are now banned from meeting together indoors. In Northern Ireland a lockdown lasting four weeks is now in force, says the Chicago Tribune.

According to the head of the World Health Organization's Europe office, “the exponential surge of cases across the continent has warranted the restrictive measures being taken, calling them ‘absolutely necessary’ to stop the pandemic,” as reported by the Associated Press.

There are fears of lockdowns in the U.S. again, too.

However, the world may be near a potential vaccine from Pfizer (PFE) and BioNTech (BNTX).

The two could be ready to file for emergency use authorization of their vaccine by mid-November 2020. As the companies near potential news on the vaccine, and on the emergency filing, BNTX and PFE could move even higher.

“"We are operating at the speed of science. This means we may know whether or not our vaccine is effective by the end of October. To do so, we must accumulate a certain number of COVID-19 cases in our trial to compare the effectiveness of the vaccine in vaccinated individuals to those who received a placebo. Since we must wait for a certain number of cases to occur, this data may come earlier or later based on changes in the infection rates," said Pfizer CEO Albert Bourla.

The companies also need to make sure the vaccine is safe. With the US FDA needing two months of safety data on half of the trial participants following final the dose of vaccine, the companies could meet that milestone by mid-November 2020.

Another Top Vaccine Stock to Consider is Moderna Inc. (MRNA)

Moderna just announced the “initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19. This initiative follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of
mRNA-1273 in healthy adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in the New England Journal of Medicine."

Also keep an eye on Inovio Pharmaceuticals (INO)

The bad news here is that there is a US FDA halt on the stock at the moment with regards to Inovio's delivery device. The good news is the halt is not because of any adverse events related to the company studies. Plus, some analysts, including those at Maxim Group, just upgraded the stock to a buy rating from a hold rating, and believe the halt will be short-lived.

Following the halt, we believe INO is a solid “blood in the streets” opportunity.